FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912625047> ?p ?o ?g. }

• W2912625047 endingPage "688" @default.
• W2912625047 startingPage "682" @default.
• W2912625047 abstract "Patients in intensive care units (ICUs) present a high risk of developing an infection caused by multidrug-resistant bacteria. Consequently, new antimicrobials and combinations are required. In this study, the activity of ceftolozane/tazobactam (C/T) was evaluated against Enterobacterales (n = 400) and Pseudomonas aeruginosa (n = 80) clinical isolates collected from patients in Spanish ICUs with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). Overall susceptibility to C/T in P. aeruginosa isolates by infection type was 95.7% in cUTI (MIC50/90, 1/4 mg/L) and 85.3% in cIAI (MIC50/90, 1/64 mg/L). Activity against P. aeruginosa was maintained regardless of its resistance pattern, confirming that C/T is one of the best antipseudomonal agents along with colistin and amikacin. Susceptibility to C/T in Enterobacterales by infection type was 79.5/81.9% and 89.3/92.3% (EUCAST/CLSI) in cIAI and cUTI isolates, respectively. Activity was excellent against wild-type organisms, with 100% susceptible and inhibited at MIC ≤1 mg/L. Nevertheless, C/T susceptibility decreased against extended-spectrum β-lactamase (ESBL)-producing isolates: Escherichia coli (80.4/84.8% susceptible by EUCAST/CLSI) and Klebsiella pneumoniae (59.1/77.3% susceptible by EUCAST/CLSI). No activity of C/T was observed in carbapenemase-producing isolates. The in vitro activity of C/T observed in this surveillance study suggests that this agent can be considered as a therapeutic option for cUTI and cIAI due to Enterobacterales and P. aeruginosa in ICU patients, particularly when carbapenemase-producing isolates are not involved." @default.
• W2912625047 created "2019-02-21" @default.
• W2912625047 creator A5001937225 @default.
• W2912625047 creator A5002353278 @default.
• W2912625047 creator A5003310248 @default.
• W2912625047 creator A5020413378 @default.
• W2912625047 creator A5023403723 @default.
• W2912625047 creator A5036220332 @default.
• W2912625047 creator A5055425458 @default.
• W2912625047 creator A5059104303 @default.
• W2912625047 creator A5070432277 @default.
• W2912625047 creator A5072261732 @default.
• W2912625047 creator A5082548129 @default.
• W2912625047 creator A5084198803 @default.
• W2912625047 date "2019-05-01" @default.
• W2912625047 modified "2023-10-18" @default.
• W2912625047 title "Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study" @default.
• W2912625047 cites W1983892079 @default.
• W2912625047 cites W1984903487 @default.
• W2912625047 cites W2091090665 @default.
• W2912625047 cites W2103382313 @default.
• W2912625047 cites W2121867408 @default.
• W2912625047 cites W2154126135 @default.
• W2912625047 cites W2339454548 @default.
• W2912625047 cites W2553674517 @default.
• W2912625047 cites W2734402341 @default.
• W2912625047 cites W2769664028 @default.
• W2912625047 cites W2773882131 @default.
• W2912625047 cites W2779985585 @default.
• W2912625047 doi "https://doi.org/10.1016/j.ijantimicag.2019.02.004" @default.
• W2912625047 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30769199" @default.
• W2912625047 hasPublicationYear "2019" @default.
• W2912625047 type Work @default.
• W2912625047 sameAs 2912625047 @default.
• W2912625047 citedByCount "35" @default.
• W2912625047 countsByYear W29126250472019 @default.
• W2912625047 countsByYear W29126250472020 @default.
• W2912625047 countsByYear W29126250472021 @default.
• W2912625047 countsByYear W29126250472022 @default.
• W2912625047 countsByYear W29126250472023 @default.
• W2912625047 crossrefType "journal-article" @default.
• W2912625047 hasAuthorship W2912625047A5001937225 @default.
• W2912625047 hasAuthorship W2912625047A5002353278 @default.
• W2912625047 hasAuthorship W2912625047A5003310248 @default.
• W2912625047 hasAuthorship W2912625047A5020413378 @default.
• W2912625047 hasAuthorship W2912625047A5023403723 @default.
• W2912625047 hasAuthorship W2912625047A5036220332 @default.
• W2912625047 hasAuthorship W2912625047A5055425458 @default.
• W2912625047 hasAuthorship W2912625047A5059104303 @default.
• W2912625047 hasAuthorship W2912625047A5070432277 @default.
• W2912625047 hasAuthorship W2912625047A5072261732 @default.
• W2912625047 hasAuthorship W2912625047A5082548129 @default.
• W2912625047 hasAuthorship W2912625047A5084198803 @default.
• W2912625047 hasConcept C104317684 @default.
• W2912625047 hasConcept C2777058267 @default.
• W2912625047 hasConcept C2777427914 @default.
• W2912625047 hasConcept C2777637488 @default.
• W2912625047 hasConcept C2778266534 @default.
• W2912625047 hasConcept C2779259085 @default.
• W2912625047 hasConcept C2779631663 @default.
• W2912625047 hasConcept C4937899 @default.
• W2912625047 hasConcept C501593827 @default.
• W2912625047 hasConcept C523546767 @default.
• W2912625047 hasConcept C54355233 @default.
• W2912625047 hasConcept C547475151 @default.
• W2912625047 hasConcept C55493867 @default.
• W2912625047 hasConcept C71924100 @default.
• W2912625047 hasConcept C86803240 @default.
• W2912625047 hasConcept C89423630 @default.
• W2912625047 hasConcept C94665300 @default.
• W2912625047 hasConceptScore W2912625047C104317684 @default.
• W2912625047 hasConceptScore W2912625047C2777058267 @default.
• W2912625047 hasConceptScore W2912625047C2777427914 @default.
• W2912625047 hasConceptScore W2912625047C2777637488 @default.
• W2912625047 hasConceptScore W2912625047C2778266534 @default.
• W2912625047 hasConceptScore W2912625047C2779259085 @default.
• W2912625047 hasConceptScore W2912625047C2779631663 @default.
• W2912625047 hasConceptScore W2912625047C4937899 @default.
• W2912625047 hasConceptScore W2912625047C501593827 @default.
• W2912625047 hasConceptScore W2912625047C523546767 @default.
• W2912625047 hasConceptScore W2912625047C54355233 @default.
• W2912625047 hasConceptScore W2912625047C547475151 @default.
• W2912625047 hasConceptScore W2912625047C55493867 @default.
• W2912625047 hasConceptScore W2912625047C71924100 @default.
• W2912625047 hasConceptScore W2912625047C86803240 @default.
• W2912625047 hasConceptScore W2912625047C89423630 @default.
• W2912625047 hasConceptScore W2912625047C94665300 @default.
• W2912625047 hasFunder F4320326262 @default.
• W2912625047 hasFunder F4320334923 @default.
• W2912625047 hasIssue "5" @default.
• W2912625047 hasLocation W29126250471 @default.
• W2912625047 hasLocation W29126250472 @default.
• W2912625047 hasOpenAccess W2912625047 @default.
• W2912625047 hasPrimaryLocation W29126250471 @default.
• W2912625047 hasRelatedWork W2075090094 @default.
• W2912625047 hasRelatedWork W2266621686 @default.
• W2912625047 hasRelatedWork W2315401976 @default.
• W2912625047 hasRelatedWork W2350151450 @default.

• next